Evidence map›Paper›PMID 18706269›Full record

ReviewCurrent oncology reports2008

Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.

Pieternella J Lugtenburg, Pieter Sonneveld

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Pieternella J LugtenburgDepartment of Hematology, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. p.lugtenburg@erasmusmc.nl
Pieter Sonneveld
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With an increasingly aged population, many patients will present with diffuse large B-cell lymphoma in their 70s and 80s. Recently, several randomized studies have confirmed the benefit of rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and showed a substantial improvement in the outcome of fit elderly patients. This article reviews the efficacy and toxicity of the current treatment regimens applied for the treatment of diffuse large B-cell lymphoma in elderly patients and provides practical recommendations for the management of these patients.

Indexed as

AgingAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsComorbidityFemaleGeriatricsHumansLymphoma, Large B-Cell, DiffuseMaleMedical OncologyPalliative CarePrognosisRituximabAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsRituximab

Identifiers

PMID18706269
OpenAlexW2084694447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.